Traders should prepare for a potentially muted reaction post-release due to lack of a conference call; monitor the earnings press release closely for any surprises in financials or pipeline updates.
SPRO drugs
SPRO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 19 $2.47entry
- T+1 · 8mo ago −4.05%α −2.31% · $2.37
- T+5 · 8mo ago −4.05%α −1.84% · $2.37
- T+20 · 7mo ago +11.34%α +3.71% · $2.75
- T+60 · 5mo ago +17.81%α +3.47% · $2.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spero Therapeutics announced it will release its Q4 and full-year 2025 financial results on March 26, 2026, after market close. The company will not host a conference call, limiting immediate investor engagement and real-time clarification of results.
Key Facts
- Spero Therapeutics will report Q4 and full-year 2025 financial results on March 26, 2026, after market close.
- No conference call is planned, which may limit investor interaction and near-term market reaction.
- Company remains focused on clinical-stage development for rare and high unmet need diseases.
Financial Impact
Results pending, no financial figures provided in this release
Risk Factors
- Lack of management commentary via conference call increases risk of misinterpretation or delayed reaction to results.
- As a clinical-stage biopharma with no commercial revenue, financial results will likely reflect continued R&D spend and cash burn.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258588 |
Track record
17 reports on SPRO
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
- Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
- Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
- Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers